See more : CONSTRONICS INFRA LIMITED (CONSTRONIC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Soligenix, Inc. (SNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soligenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Invesco Mortgage Capital Inc. (IVR-PB) Income Statement Analysis – Financial Results
- ClimateRock (CLRCU) Income Statement Analysis – Financial Results
- Associated Banc-Corp (ASB-PE) Income Statement Analysis – Financial Results
- Polyplex Corporation Limited (POLYPLEX.BO) Income Statement Analysis – Financial Results
- Powerwrap Limited (PWL.AX) Income Statement Analysis – Financial Results
Soligenix, Inc. (SNGX)
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | 5.24M | 5.43M | 10.45M | 8.77M | 7.04M | 3.22M | 3.14M | 7.66M | 1.95M | 2.82M | 2.31M | 1.26M | 2.31M | 3.08M | 997.48K | 83.82K | 0.00 | 0.00 | 0.00 | 1.00 | 200.00K | 100.00K | 0.00 |
| Cost of Revenue | 742.05K | 550.82K | 728.64K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M | 6.88M | 5.31M | 2.54M | 2.59M | 2.11M | 1.64M | 1.48M | 1.89M | 943.39K | 1.97M | 2.07M | 936.64K | 76.20K | 0.00 | 0.00 | 0.00 | -1.41M | -1.70M | -500.00K | 0.00 |
| Gross Profit | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | 643.73K | 1.12M | 2.02M | 1.89M | 1.73M | 679.87K | 551.55K | 5.55M | 309.23K | 1.33M | 423.83K | 314.63K | 347.95K | 1.01M | 60.85K | 7.62K | 0.00 | 0.00 | 0.00 | 1.41M | 1.90M | 600.00K | 0.00 |
| Gross Profit Ratio | 11.59% | 41.95% | 11.60% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | 15.88% | 47.31% | 18.35% | 25.01% | 15.04% | 32.80% | 6.10% | 9.09% | 0.00% | 0.00% | 0.00% | 140,775,100.00% | 950.00% | 600.00% | 0.00% |
| Research & Development | 3.31M | 7.94M | 8.39M | 15.15M | 8.12M | 6.75M | 5.51M | 4.30M | 5.40M | 5.09M | 5.07M | 2.61M | 6.27M | 5.68M | 4.52M | 1.73M | 3.10M | 4.62M | 3.68M | 3.66M | 2.73M | 2.94M | 2.47M | 956.74K | 2.03M | 3.10M | 1.80M | 906.46K |
| General & Administrative | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.56M | 0.00 | 2.50M | 2.86M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 2.51M | 1.97M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 2.50M | 2.86M | 2.15M | 3.54M | 3.11M | 2.16M | 2.32M | 2.51M | 2.99M | 1.97M | 2.10M | 3.05M | 3.50M | 1.50M | 317.24K |
| Other Expenses | 0.00 | -132.87K | -174.77K | -95.36K | -433.59K | 0.00 | 0.00 | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 0.00 | 0.00 | 0.00 | 3.54M | 3.93M | 2.16M | 2.32M | 2.51M | 2.99M | 12.15M | 2.10M | 4.45M | 5.20M | 2.00M | 0.00 |
| Operating Expenses | 7.80M | 14.50M | 13.06M | 19.03M | 11.17M | 9.70M | 8.72M | 7.72M | 9.00M | 8.49M | 7.84M | 5.24M | 8.51M | 8.19M | 7.38M | 3.88M | 6.64M | 8.55M | 5.84M | 5.98M | 5.23M | 5.93M | 14.63M | 3.06M | 6.48M | 8.30M | 3.80M | 1.26M |
| Cost & Expenses | 8.54M | 15.05M | 13.79M | 20.85M | 14.74M | 14.30M | 13.03M | 16.16M | 15.88M | 13.80M | 10.38M | 7.84M | 10.62M | 9.83M | 8.87M | 5.77M | 7.59M | 10.51M | 7.91M | 6.91M | 5.31M | 5.93M | 14.63M | 3.06M | 5.08M | 6.60M | 3.30M | 1.26M |
| Interest Income | 0.00 | 822.61K | 904.50K | 10.88K | 148.97K | 159.01K | 29.91K | 0.00 | 0.00 | 1.31K | 1.96K | 6.20K | 7.44K | 12.07K | 21.92K | 37.07K | 164.85K | 41.51K | 114.79K | 66.54K | 28.71K | 105.68K | 424.03K | 747.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.13K | 822.61K | 862.58K | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 742.00 | 2.68K | 3.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -35.84K | -35.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55K | 137.28K | 150.45K | 193.04K | 177.56K | 44.06K | 68.56K | 89.93K | 247.46K | 245.79K | 230.07K | 230.63K | 226.03K | 185.70K | 175.60K | 149.18K | 119.57K | 137.04K | 194.28K | 302.45K | 226.14K | 345.50K | 188.53K | 156.86K | 1.41M | 1.70M | 500.00K | 204.46K |
| EBITDA | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | -9.01M | -7.53M | -5.62M | -6.86M | -6.52M | -6.93M | -4.45M | -2.73M | -7.45M | -5.86M | -3.31M | -6.21M | -8.02M | -4.64M | -5.61M | -5.00M | -6.45M | -3.86M | -2.90M | -3.67M | -4.80M | -2.70M | -1.06M |
| EBITDA Ratio | -935.58% | -1,483.34% | -1,565.17% | -781.06% | -216.96% | -171.99% | -138.52% | -72.27% | -64.56% | -84.51% | -101.47% | -141.83% | -35.58% | -394.36% | -208.57% | -143.13% | -493.33% | -313.28% | -150.88% | -562.94% | -5,934.78% | 0.00% | 0.00% | 0.00% | -80,576,000.00% | 5,250.00% | -2,900.00% | 0.00% |
| Operating Income | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | -9.06M | -7.59M | -5.71M | -7.11M | -10.76M | -7.16M | -4.69M | -2.96M | -7.88M | -6.05M | -3.46M | -6.33M | -8.20M | -4.84M | -5.92M | -5.23M | -5.93M | -14.63M | -3.06M | -5.08M | -6.40M | -3.20M | -1.26M |
| Operating Income Ratio | -917.12% | -1,486.55% | -1,573.05% | -783.71% | -218.31% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | -404.51% | -214.89% | -149.59% | -502.94% | -354.50% | -157.20% | -593.21% | -6,236.06% | 0.00% | 0.00% | 0.00% | -507,562,800.00% | -3,200.00% | -3,200.00% | 0.00% |
| Total Other Income/Expenses | -210.59K | -714.37K | -449.60K | 61.09K | 574.75K | 159.01K | 29.91K | 1.93M | -1.21M | 3.44M | -3.65M | 6.20K | 7.44K | 246.03K | 16.84K | 33.80K | 162.44K | 36.20K | 114.79K | 45.54K | -61.65K | -5.92K | -5.92K | -2.43M | -2.86M | -15.20M | 200.00K | 74.85K |
| Income Before Tax | -7.91M | -14.95M | -13.42M | -18.53M | -9.97M | -8.90M | -7.56M | -3.78M | -8.32M | -7.32M | -10.81M | -4.68M | -2.95M | -7.63M | -6.05M | 0.00 | -6.33M | -9.02M | 0.00 | -5.92M | -5.29M | -14.63M | -14.63M | -5.49M | -7.94M | -21.60M | -3.00M | -1.19M |
| Income Before Tax Ratio | -942.21% | -1,575.84% | -1,627.59% | -785.16% | -215.26% | -169.80% | -139.23% | -36.13% | -94.89% | -103.99% | -335.26% | -148.97% | -38.53% | -391.88% | -214.97% | 0.00% | -503.05% | -389.79% | 0.00% | -593.15% | -6,309.62% | 0.00% | 0.00% | 0.00% | -793,774,600.00% | -10,800.00% | -3,000.00% | 0.00% |
| Income Tax Expense | -1.77M | -1.15M | -864.74K | -836.89K | -610.68K | 159.01K | -416.81K | -530.14K | -488.93K | -616.87K | -750.36K | -521.46K | -574.16K | -245.81K | -16.84K | -33.80K | -162.44K | -36.20K | -114.79K | -45.54K | 61.65K | -965.43K | 5.92K | 1.74M | 2.43M | 15.40M | 0.00 | 0.00 |
| Net Income | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M | -8.90M | -7.15M | -3.25M | -7.83M | -6.71M | -10.06M | -4.16M | -2.38M | -7.39M | -6.03M | -3.42M | -6.16M | -8.16M | -4.72M | -5.87M | -5.29M | -4.97M | -14.63M | -4.80M | -7.50M | -21.80M | -3.20M | -1.19M |
| Net Income Ratio | -731.60% | -1,454.12% | -1,522.68% | -749.69% | -202.07% | -169.80% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | -379.26% | -214.29% | -148.12% | -490.03% | -352.93% | -153.47% | -588.64% | -6,309.62% | 0.00% | 0.00% | 0.00% | -750,101,900.00% | -10,900.00% | -3,200.00% | 0.00% |
| EPS | -12.66 | -76.96 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -223.73 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| EPS Diluted | -12.66 | -76.89 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -320.56 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| Weighted Avg Shares Out | 484.88K | 179.29K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 10.12K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
| Weighted Avg Shares Out (Dil) | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 14.93K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
Why Is Soligenix (SNGX) Stock Up 296% Today?
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Tuesday following positive data from the late-stage biopharmaceutical company's extended HyBryte treatment. This data interim data comes from a 12-month study testing HyBryte as a treatment for early-stage cutaneous T-cell lymphoma...
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June...
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare...
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its...
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...
Source: https://incomestatements.info
Category: Stock Reports